Teriparatide, recombinant human PTH (1–34), is approved by the United States Food and Drug Administration (FDA) for initial treatment of post-menopausal osteoporosis with a high risk of fracture for patients who have failed prior osteoporosis therapy and for adults with GC-associated osteoporosis (117). This evidence concerns the gene PTH and osteoporosis.